Loading...

Eli Lilly's Indiana Manufacturing Expansion: Where Connected Manufacturing Fits

Manufacturing IoT

Published by IOT Indiana Research & Editorial Team

Eli Lilly's Indiana Manufacturing Expansion: Where Connected Manufacturing Fits

Eli Lilly's building program in Lebanon, Indiana is one of the largest pharmaceutical manufacturing efforts in the country, and it is happening about 28 miles from the company's Indianapolis headquarters. For people who work in industrial automation and connected manufacturing, the interesting question is not the size of the checks. It is what a modern drug plant has to measure, record and prove, and how much of that work falls to technology that Indiana firms already know.

Lilly has not published the control architecture of these plants, so this article does not describe its internal systems. It describes how regulated pharmaceutical manufacturing generally works, ties that to what Lilly has said publicly, and points to practical openings for Indiana engineers, integrators and suppliers.

What Lilly has said publicly about Lebanon

According to reporting on Lilly's announcements, the company is developing three facilities on roughly 600 acres in the LEAP Research and Innovation District. Lilly has described the complex as a cornerstone of its U.S. production buildout.

FacilityRoleReported status
Lilly Lebanon Advanced TherapiesGenetic medicine clinical and commercial productionFirst of the three to become operational
Lilly Lebanon APIActive pharmaceutical ingredient for tirzepatide, the drug in Mounjaro and Zepbound, plus support for other pipeline medicinesUnder construction; Lilly calls it the largest API plant in the U.S.
Lilly Medicine FoundryR&D and clinical trial manufacturing for small molecules and biologics, about 1.2 million square feetScheduled for completion in 2027

Lilly announced an additional $4.5 billion to expand two of the three Lebanon facilities, on top of the $4.5 billion cost it set for the Medicine Foundry in 2024. Reporting also says more than $21 billion of Lilly's domestic commitment has been allocated to Indiana overall. Treat all figures as company statements and check Lilly's own releases for updates.

Why connected manufacturing looks different in pharma

In an automotive plant, a data problem usually means scrap or rework. In a drug plant, a data problem can mean a quarantined batch, a failed inspection or a delayed medicine. That changes what "connected" means. Three ideas dominate.

Data integrity is the product

Regulators expect records to be attributable, legible, contemporaneous, original and accurate, with the related principles of complete, consistent, enduring and available often grouped as ALCOA+. Electronic records and signatures fall under rules such as FDA 21 CFR Part 11. For connected devices, this means every sensor reading used for a quality decision needs a trustworthy path from the instrument to the record, with time stamps, access control and audit trails.

Validation precedes value

Systems that affect product quality are validated, which means installation, operational and performance qualification are documented before use. Adding a sensor is rarely a casual act. Changes follow formal change control. That slows deployment compared with other industries, but it also means well-designed, standards-based systems can run for many years.

Process knowledge beats raw volume

Modern pharma plants generate enormous sensor streams, but the goal is process understanding: knowing which parameters influence quality and holding them in the right range. Many companies use process analytical technology, which measures quality attributes during manufacturing rather than waiting for end-of-batch testing, and continued process verification, which keeps checking that a process stays in a state of control.

Where connected technology fits in each type of site

API production

Active ingredient plants involve reactors, filtration, chromatography, crystallization, drying and solvent handling. Typical instrumentation covers temperature, pressure, flow, pH, conductivity and level, with analyzers for concentration and purity. Hazardous area classification, since solvents are flammable, shapes equipment choices. Utilities such as purified water, clean steam, chilled water and nitrogen are monitored continuously. A very large API plant makes energy and solvent recovery important, so metering has financial as well as quality value.

Genetic medicine and biologics

Cell and gene therapy and biologic manufacturing rely on bioreactors, single-use systems, filtration and fill-finish steps. Sensors track pH, dissolved oxygen, temperature, agitation and pressure, and many products are very sensitive to deviations. Lilly has noted that its genetic medicine plant required processes with no established commercial precedent, which tends to increase the value of rich process data.

R&D and clinical manufacturing

A facility that supports both development and clinical supply needs flexibility. Equipment is reconfigured often, and recipes change. Connected systems here need strong version control and clear records of which equipment configuration produced which batch.

Six connected-manufacturing layers to expect

  1. Environmental monitoring. Particle counts, differential pressure, temperature and humidity in cleanrooms, with alarms and trending. Classification follows standards such as ISO 14644 and, for sterile work, additional regulatory requirements.
  2. Utilities monitoring. Water for injection and purified water loops, clean steam, HVAC and compressed gases, where temperature, conductivity, flow and microbial control matter.
  3. Equipment connectivity. Bioreactors, chromatography skids, filling lines and packaging machines send data to historians and execution systems, often through OPC UA or vendor-specific interfaces.
  4. Manufacturing execution. Electronic batch records guide operators through steps, capture checks and enforce sequence, reducing paper and errors.
  5. Quality and laboratory systems. Laboratory information systems link samples, tests and results to batch release decisions.
  6. Supply chain visibility. Temperature-controlled storage and shipping, serialization and track-and-trace for finished products, which matters especially for injectable and cold-chain medicines.

What Indiana firms can credibly offer

The Lebanon program will draw heavily on national and global engineering firms, equipment makers and validation specialists. Local companies tend to find work around the edges, which still add up to a great deal over a plant's life.

  • Instrumentation and calibration. A pharma plant has thousands of instruments on calibration schedules. Local metrology labs and field technicians with documented procedures are in demand.
  • Controls and automation support. Integrators who understand validated environments can support upgrades, troubleshooting and expansion once plants are operating.
  • Cleanroom and facility maintenance. HVAC, filtration, door interlocks and pressure control systems need skilled maintenance and meticulous records.
  • Network and cybersecurity services. Segmented networks and secure remote access are mandatory, and specialized support is scarce.
  • Cold chain and logistics. Indiana's logistics position supports temperature-controlled storage and transport, with data loggers and real-time tracking.
  • Training. Technicians who understand both manufacturing equipment and regulatory expectations are among the hardest roles to fill.

A worked example: calibration scheduling with sensor health data

The following is an illustrative scenario with invented numbers. A pharmaceutical plant has 4,000 calibrated instruments, each checked at fixed intervals. A service company proposes adding drift analytics: instead of simply calibrating on a calendar, it compares each instrument's readings with redundant or related measurements and flags those that appear to be drifting.

  • Most instruments continue on the fixed schedule, as required by the plant's procedures.
  • A small group of instruments shows early drift. Technicians investigate sooner, avoiding the risk that product was made with an out-of-tolerance reading.
  • The plant records the investigation, which strengthens its quality story rather than weakening it.

The value is not fewer calibrations, since the plant must still follow its approved schedule. The value is earlier detection and a cleaner record. Any such change would go through the plant's change control and validation, so vendors should arrive with documentation, not just a demo.

Network design and security in a regulated plant

Pharmaceutical plants usually separate their networks into zones: business systems, manufacturing operations, process control and, where needed, isolated enclaves for highly sensitive equipment. This follows the same layered thinking as the Purdue Model and IEC 62443 zones and conduits. Data crosses from one zone to the next only through controlled points such as firewalls, data diodes or historian mirrors.

For an integrator, that has practical consequences. Remote support is rarely a direct connection from a laptop. It runs through approved, logged sessions with time-limited access. Patches are tested before they reach production systems, and some devices must stay on a validated software version for years. Wireless sensors need a documented radio survey and a clear answer to what happens when a signal drops during a batch.

Security is also a quality matter. If an unauthorized change could alter a recipe or a record, the consequences reach product quality, not just IT. Teams that explain their design in those terms, rather than as generic security promises, earn trust faster.

Questions to ask before pitching a pharma plant

  • Which systems in this area are validated, and who owns the validation documentation?
  • What is the approved process for introducing a new device or software version?
  • Which records are considered GMP records, and where must they be stored?
  • How are time stamps synchronized across equipment and software?
  • What are the expectations for backup, disaster recovery and data retention periods?
  • Who must approve vendor access, and how is that access logged?

Asking these questions early shows respect for the customer's process and prevents proposals that cannot be approved.

Common mistakes vendors make in pharma

  • Treating validation as the customer's problem. Provide installation and test documentation, version histories and clear release notes.
  • Selling cloud-first without answers. Quality and IT teams will ask where data lives, how it is backed up and how audit trails are protected.
  • Underestimating cleanroom rules. Gowning, cleaning and material transfer procedures affect schedules and cost.
  • Ignoring human factors. Interfaces that confuse operators create deviations, and deviations create paperwork.
  • Overpromising AI. Analytics must be explainable and validated for any decision that affects quality.

What to watch

Several milestones will shape the opportunity: operational status of the API plant, the Foundry's 2027 completion, hiring announcements, and Lilly's supplier outreach. Also watch regional impacts, including competition for skilled technicians and utility capacity. Lebanon sits in the same district as Meta's data center campus, so labor, power and water demand will overlap, a topic we cover in our pieces on Indiana data center demand.

Lilly has said that every Lilly job supports more than two other jobs in Indiana. That is a company claim, but the direction is plausible: large plants support a wide ring of services. Companies preparing now, by documenting quality systems and building experience with regulated environments, will be better placed when purchasing begins.

The bottom line

Connected manufacturing in pharma is less about flashy dashboards and more about trustworthy data, validated systems and disciplined change control. Lilly's Lebanon expansion will create years of demand for exactly that discipline across instrumentation, automation, facilities and logistics. Indiana companies that learn the regulatory vocabulary and offer documented, standards-based services have a real chance to become part of the supply chain.

Frequently asked questions

Lilly has described three facilities in the LEAP Research and Innovation District on about 600 acres: Lilly Lebanon Advanced Therapies for genetic medicine, Lilly Lebanon API for active ingredient production including tirzepatide, and the Lilly Medicine Foundry for R&D and clinical trial manufacturing. The genetic medicine plant was reported as the first to become operational, with the Foundry scheduled for 2027.

It means linking equipment, sensors, utilities, laboratory systems and batch records so data flows reliably to people who need it. The emphasis is on data integrity, validated systems and traceability, since records support quality and regulatory decisions.

Systems that affect product quality are validated and controlled by formal change management, so a new sensor needs documentation, testing and approval. Data must also meet integrity expectations such as ALCOA+ and electronic record rules like 21 CFR Part 11.

Start with GMP principles, 21 CFR Part 11, ALCOA+ data integrity, ISO 14644 for cleanrooms, and ISA-95 for connecting plant-floor and business systems. Industrial cybersecurity guidance such as IEC 62443 is also commonly expected.

Yes, often in supporting roles such as instrument calibration, controls maintenance, cleanroom and facility services, cybersecurity, cold chain logistics and training. Success usually depends on documented procedures, quality systems and experience working in regulated environments.

They come from reporting on Lilly's announcements, including figures for the $4.5 billion expansion and the Medicine Foundry. They are company statements, so check Lilly's own releases and filings for the latest numbers and timelines.

Related articles

Top